Clinical trial · Observational
Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers
Plasma Quantification of Cathepsin D and FAS in Non-Small Cell Lung Cancer
NCT00897234CI-TRIAL-00015447completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from patients with non-small cell lung cancer and from healthy volunteers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mass Spectrometry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Healthy Volunteers
- description
- Non-smoking healthy volunteers
- interventionNames
- Other: Mass Spectrometry
- label
- Non-Small Cell Lung Cancer
- description
- Patients with non-small cell lung cancer.
- interventionNames
- Other: Mass Spectrometry
Primary outcomes (1)
- measure
- Levels of cathepsin D
- timeFrame
- At Routine Follow-Up
- description
- Measure plasma CD levels in patients with non-small cell lung cancer and non-smoker healthy controls using mass spectrometry.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Non-Small Cell Lung Cancer Patients * Documented diagnosis of non-small cell lung cancer, any stage and any time point in the course of treatment (i.e., at diagnosis, during any treatment, and during post treatment surveillance) * Measurable disease by CT scan within the past 4 weeks Healthy volunteer * Non-smoking, defined as \< 5 packs/year history of smoking and cessation of smoking ≥ 6 months ago OR a never smoker * Not regularly exposed (i.e., daily) to second-hand smoke Exclusion Criteria: * Severe underlying lung disease (i.e., chronic obstructive pulmonary disease with FEV\_1 \< 1.0 L, pulmonary fibrosis, bronchiectasis, cystic fibrosis, etc.) as determined by enrolling researcher. Written consent must be given for both subjects and controls.
References
Publications (0)
Data not yet available
No reference posted for this study.